MedPath

Syndesi Therapeutics

πŸ‡§πŸ‡ͺBelgium
Ownership
-
Employees
-
Market Cap
-
Website

A Study of SDI-118 in Participants in Remission From Depression

Phase 1
Withdrawn
Conditions
Depression in Remission
Interventions
Drug: Placebo
First Posted Date
2022-01-27
Last Posted Date
2022-04-22
Lead Sponsor
Syndesi Therapeutics
Registration Number
NCT05212116
Locations
πŸ‡¬πŸ‡§

University of Manchester, Manchester, Lancashire, United Kingdom

πŸ‡¬πŸ‡§

Cardiff University, Cardiff, Wales, United Kingdom

πŸ‡¬πŸ‡§

University of Oxford, Oxford, Oxfordshire, United Kingdom

A Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of SDI-118 in Elderly Male and Female Study Participants With Cognitive Decline

Phase 1
Terminated
Conditions
Cognitive Decline
Interventions
Drug: Placebo
First Posted Date
2022-01-20
Last Posted Date
2022-04-22
Lead Sponsor
Syndesi Therapeutics
Target Recruit Count
5
Registration Number
NCT05199142
Locations
πŸ‡©πŸ‡ͺ

University Hospital Frankfurt, Frankfurt am Main, Germany

πŸ‡¬πŸ‡§

St Pancras Clinical Research, London, United Kingdom

Β© Copyright 2025. All Rights Reserved by MedPath